Therefore, we conducted a retrospective study to compare the efficacy and survival of trastuzumab combined with chemotherapy versus anti-PD-1 antibody combined with trastuzumab and chemotherapy in patients with HER2-positive gastric adenocarcinoma. Here, ERBB2 is linked to gastric adenocarcinoma.